Supplementary Material for: Clinicopathological Features Associated with Microsatellite Instability/Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Quantitative Systematic Review

  • Antonio Travaglino (Contributor)
  • Antonio Raffone (Contributor)
  • Angela Santoro (Contributor)
  • Diego Raimondo (Contributor)
  • Benedetta Orsini (Contributor)
  • Paolo Casadio (Contributor)
  • Fulvio Zullo (Contributor)
  • Renato Seracchioli (Contributor)
  • Gian Franco Zannoni (Contributor)
  • Luigi Insabato (Contributor)
  • Antonio Mollo (Contributor)

Dataset

Description

Introduction: Recent studies suggested that microsatellite instability/mismatch repair deficiency (MSI/MMR-d) might define a clinicopathologically distinct subset of uterine carcinosarcomas (UCSs). Objective: The aim of this study was to compare clinicopathological features between MSI/MMR-d and microsatellite-stable/mismatch repair-proficient (MSS/MMR-p) UCSs. Methods: A quantitative systematic review was performed by searching electronic databases from January 2000 to January 2021. All studies assessing MSI/MMR status in UCS were included. Odds ratio (OR) with a significant two-tailed p value 60 (p = 0.034), serous carcinoma component (pure: p < 0.001; pure + mixed: p < 0.001), heterologous sarcoma component (p = 0.027), TP53-mutation/p53-abnormal expression (p < 0.001), and recurrence (p < 0.001). MSI/MMR-d showed no significant association with advanced FIGO stage (OR = 1.259; p = 0.517), low-grade carcinoma component (pure: p = 0.596; pure + mixed: p = 0.307), mixed carcinoma component (p = 1), and proportion of patients “dead of disease” (p = 0.352), “alive with disease” (p = 1) or with “no evidence of disease” (p = 0.458). Conclusion: MSI/MMR-d UCSs show younger age, more common endometrioid, undifferentiated or clear cell carcinoma component, and less common serous carcinoma component, heterologous sarcoma component, and TP53 mutation than MSS/MMR-p UCSs. Given the discrepancy between recurrence rate and oncologic outcomes at the last follow-up, further studies are necessary to define whether MSI/MMR-d UCSs have better prognosis.
Dati resi disponibili2022
EditoreKarger Publishers

Cita questo